May 22, 2023
Immunize.org president and CEO Kelly Moore, MD, MHP, describes the holistic view the ACIP will take of the virus, the vaccine, and the overall economics of the immunization.
May 19, 2023
Statin therapy initiated within 1 year of diagnosis of atrial fibrillation reduced the risk of ischemic stroke or systemic embolism by nearly 20%.
May 19, 2023
The Pfizer vaccine RSVpreF administered to pregnant people was judged by the advisory committee to be effective at preventing RSV in infants from birth to 6 months.
May 19, 2023
Kelly Moore, MD, MPH, says the public health community is relieved by the FDA's approval and excited at "the chance to finally do something about the disease."
May 17, 2023
Patients with rheumatoid arthritis and fibromyalgia were at the greatest risk of transitioning to long-term opioid use 1 year after a first prescription, a new study found.
May 17, 2023
The label expansion is based on findings from the pivotal phase 3 DELIVER trial in which dapagliflozin reduced the composite CV/HF endpoint in HF patients with HFmrEF or HFpEF.
May 16, 2023
Women's Health Week (May 14-20, 2023) is an ideal opportunity to review the top research, policy shifts, and potential drug approvals that affect your patient panel.
May 16, 2023
Scott Laker, MD, vice president of the AAPM&R, offers 3 thoughts on what primary care clinicians should think of when they think about PM&R.
May 12, 2023
USPSTF says start mammograms 10 years earlier, OTC contraceptive coming soon, another antiobesity drug in the wings, and 2 more weekly updates of note.
May 12, 2023
Brexpiprazole, an atypical antipsychotic, is the first and only medication approved to treat AD-associated agitation, reported in almost half of people with the disease.